Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5401_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
15.09.2026
Размер:
14 Мб
Скачать
☆
454 Herbal Pharmacopeia
the compounding formulation and practices. To ensure the effectiveness of safety measures, pre­market and post- market surveillance is required [49]. Accordingly, there must be rules for checking the cytotoxicity of personalized medicine through cell culture techniques. Regulatory bodies must require the manufacturer to conduct clinical trials for the effectiveness and side effects analysis of personalized medicines.
The regulatory implication includes introducing standards for the cultivation, harvesting, and consumption of the herbal products. Certication for the harvesting of the herbal products will help consumers to make informed choices and encourage manufacturers to adopt ethical practices [49]. Traceability and transparency in the supply chain of herbal products verify the sustainability of practices. Finally, regulations for the monitoring of conservation efforts with regard to endangered species help to achieve sustainability. Currently, the Convention on the International Trade in Endangered Species of Wild Flora and Fauna is the one of the main practical examples of sustain­ability [50].

21.15 SUSTAINABLE AND ETHICAL SOURCING

In the regulatory framework around herbal products, the sustainability and ethical sourcing of ingre­dients is a key factor. Both consumers and regulatory bodies are obliged to consider the sensitivity of prioritizing environmental and social responsibilities [51]. The unavailability and diversity loss of the herbal product due to overharvesting and unsustainable farming are among the major reasons for the decline in herbal products when this occurs. Accordingly, regulations must be put in place for sustainable and ethical sourcing.

21.16 CONCLUSION

In the area of herbal products and pharmaceuticals, a number of different regulatory bodies are play­ing major roles in the development of a comprehensive pharmacopeia. These bodies have divergent approaches to the development of rules and regulations for product development, which is acting as an obstacle to harmonization. The World Health Organization is playing a key role in trying to establish a global framework to achieve this. Any herbal pharmacopeia will have to consist of both traditional and modern knowledge and the integration of these two approaches will enhance the efcacy and safety of the herbal product. With the development of a suitable regulatory framework, the trend of personalized medicine, and ethical data resourcing and sustainability, will be effectively addressed and able to meet the needs of consumers.

21.17 FUTURE OUTLOOK FOR THE REGULATORY FRAMEWORK

In the future, the regulatory framework for herbal products will continue to evolve, incorporating advances in technology [52]. The focus of the regulatory bodies is for personalized medicine with a greater emphasis on environmental and health sustainability. The increased collaboration of the major regulatory bodies on international forums is one of the main goals for the future. Along with this, there should be support for the innovation and mutual benets for the consumers and practitio­ners which are aligned with the objectives of the regulatory framework and agencies [53].

REFERENCES

1. Ernst E. Herbal medicines: balancing benets and risks. Novartis Foundation symposium. 2007;282:154–67
2. Pal SK, Shukla Y. Herbal medicine: current status and the future. Asian Pacic journal of cancer preven-
tion: APJCP. 2003;4(4):281–8.
3. Williams CT. Herbal Supplements: Precautions and Safe Use. The Nursing clinics of North America.
2021;56(1):1–21.
Regulatory Considerations for Herbal Products 455
4. US Food and Drugs Administration. Approval letter Veregen™ Ointment, 15%, NDA 021902. 2006.
5. Heinrich M. Quality and safety of herbal medical products: regulation and the need for quality assurance
along the value chains. British Journal of Clinical Pharmacology. 2015;80(1):62–6.
6. Wang G. Awards- Herbal, Traditional & Alternative Medicine 2020. Asian Journal of Plant Science &
Research. 2020;9:2
7. Mawere M. Ethical quandaries in spiritual healing and herbal medicine: A critical analysis of the moral-
ity of traditional medicine advertising in southern African urban societies. Pan African Medical Journal. 2011;10.
8. Wah CL, Hock SC, Yun TK. Current scientic status and regulatory control of traditional/herbal medici-
nal products: Globalization challenges. Pharmaceutical Engineering 2012;32(6):10–20.
9. Healy MJ, Tong W, Ostroff S, Eichler H- G, Patak A, Neuspiel M, et al. Regulatory bioinformatics for
food and drug safety. Regulatory Toxicology and Pharmacology. 2016;80:342–7.
10. Thakkar S, Anklam E, Xu A, Ulberth F, Li J, Li B, et al. Regulatory landscape of dietary supplements and
herbal medicines from a global perspective. Regulatory Toxicology and Pharmacology. 2020;114:104647.
11. Mahady GB. Global Harmonization of Herbal Health Claims. The Journal of Nutrition. 2001;131(3):
1120S–3S.
12. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine
in the United States—prevalence, costs, and patterns of use. New England journal of medicine. 1993; 328(4):246–52.
13. United States Food and Drug Administration. New dietary ingredients notication process. Washington,
DC: US Food and Drug Administration Available online at: http:// www. fda. gov/ Food/ Dietary Supplements/ NewDietaryIngredientsNoticationProcess. 2016.
14. Denham BE. Dietary supplements—regulatory issues and implications for public health. Jama. 2011;
306(4):428–9.
15. Ross S. Functional foods: the Food and Drug Administration perspective. The American journal of clini-
cal nutrition. 2000;71(6):1735S–1738S.
16. FDA. Dietary Supplements: New Dietary Ingredient Notications and Related Issues: Guidance for
Industry: FDA. 2016.
17. Walji R, Boon H. Natural health product regulations: perceptions and impact. Trends in Food Science &
Technology. 2008;19(9):494–497.
18. European Parliament and Councill. Directive 2002/46/EC of the European Parliament and of the Council
of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements. The Ofcial Journal of the European Union 2002;183:51.
19. World Health Organization. WHO traditional medicine strategy: 2014-2023: World Health Organization;
2013.
20. Schroeder T. Chinese regulation of traditional Chinese medicine in the modern world: can the Chinese
effectively prot from one of their most valuable cultural resources? Pacic Rim Law & Policy Journal 2002;11:687.
21. Liang Z, Hu H, Li J, Yao D, Wang Y, Ung COL. Advancing the regulation of traditional and complemen-
tary medicine products: A comparison of ve regulatory systems on traditional medicines with a long history of use. Evidence- Based Complementary and Alternative Medicine. 2021;2021(1):5833945.
22. China NMPAO. Requirements for Registration, Categories and Application Documents of Traditional
Chinese Medicine. National Medical Products Administration of China Beijing, China; 2020.
23. Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Safety 1994, 10:93–102.
24. Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Safety. 1994;10(2):93–102.
25. Leung P- C, Xue C, Cheng Y. Clinical trials using Chinese medicine. A Comprehensive Guide to Chinese
Medicine. 2003:275–300.
26. Lewith GT, Jonas WB, Walach H. Clinical research in complementary therapies: Principles, problems
and solutions: Elsevier Health Sciences; 2010.
27. Verma N. Current regulatory challenges and approaches in the registration of herbal drugs in Europe.
Clinical Research and Regulatory Affairs. 2016;33(1):9–24.
28. Drezner DW. Globalization, harmonization, and competition: the different pathways to policy conver-
gence. Journal of European Public Policy. 2005;12(5):841–59.
29. Drichoutis AC, Lazaridis P, Nayga Jr RM. Consumers' use of nutritional labels: a review of research stud-
ies and issues. The Academy of Marketing Science Review 2006;2006:1.
456 Herbal Pharmacopeia
30. Mukherjee PK, Bahadur S, Chaudhary SK, Kar A, Mukherjee K. Quality related safety issue- evidence-
based validation of herbal medicine farm to pharma. Evidence- based validation of herbal medicine: Elsevier; 2015. p. 1–28.
31. Saggar S, Mir PA, Kumar N, Chawla A, Uppal J, Kaur A. Traditional and herbal medicines: opportunities
and challenges. Pharmacognosy Research. 2022;14(2), 107–114.
32. Karunamoorthi K, Jegajeevanram K, Vijayalakshmi J, Mengistie E. Traditional medicinal plants: a
source of phytotherapeutic modality in resource- constrained health care settings. Journal of Evidence- Based Complementary & Alternative Medicine. 2013;18(1):67–74.
33. Klein- Junior LC, de Souza MR, Viaene J, Bresolin TM, de Gasper AL, Henriques AT, et al. Quality
control of herbal medicines: From traditional techniques to state- of- the- art approaches. Planta medica. 2021;87(12/13):964–88.
34. Seger C, Sturm S, Stuppner H. Mass spectrometry and NMR spectroscopy: modern high- end detectors
for high resolution separation techniques–state of the art in natural product HPLC- MS, HPLC- NMR, and CE- MS hyphenations. Natural Product Reports. 2013;30(7):970–87.
35. Lemonnier N, Zhou G- B, Prasher B, Mukerji M, Chen Z, Brahmachari SK, et al. Traditional knowledge-
based medicine: a review of history, principles, and relevance in the present context of P4 systems medi­cine. Progress in Preventive Medicine. 2017;2(7):e0011.
36. Fokunang C, Ndikum V, Tabi O, Jiofack R, Ngameni B, Guedje N, et al. Traditional medicine: past,
present and future research and development prospects and integration in the National Health System of Cameroon. African Journal of Traditional, Complementary and Alternative Medicines. 2011;8(3).
10.4314/ajtcam.v8i3.65276
37. Brodnig G, Mayer- Schönberger V. Bridging the gap: the role of spatial information technologies in
the integration of traditional environmental knowledge and western science. The Electronic Journal of Information Systems in Developing Countries. 2000;1(1):1–15.
38. Kennedy G, Wang Z, Maundu P, Hunter D. The role of traditional knowledge and food biodiversity to
transform modern food systems. Trends in Food Science & Technology. 2022;130:32–41.
39. Casimirri G, editor Problems with integrating traditional ecological knowledge into contemporary
resource management. Submitted to the XII World Forestry Congress; 2003.
40. Sen S, Chakraborty R. Revival, modernization and integration of Indian traditional herbal medicine
in clinical practice: Importance, challenges and future. Journal of Traditional and Complementary Medicine. 2017;7(2):234–44.
41. Sarma N, Upton R, Rose U, Guo D- a, Marles R, Khan I, et al. Pharmacopeial standards for the qual-
ity control of botanical dietary supplements in the United States. Journal of Dietary Supplements. 2023;20(3):485–504.
42. Wang H, Chen Y, Wang L, Liu Q, Yang S, Wang C. Advancing herbal medicine: enhancing product qual-
ity and safety through robust quality control practices. Frontiers in Pharmacology. 2023;14:1265178.
43. Muyumba N, Mutombo S, Sheridan H, Nachtergael A, Duez P. Quality control of herbal drugs and prepa-
rations: The methods of analysis, their relevance and applications. Talanta Open. 2021;4:100070.
44. He T- T, Ung COL, Hu H, Wang Y- T. Good manufacturing practice (GMP) regulation of herbal medicine
in comparative research: China GMP, cGMP, WHO- GMP, PIC/S and EU- GMP. European Journal of integrative Medicine. 2015;7(1):55–66.
45. Shinde VM, Dhalwal K, Potdar M, Mahadik KR. Application of quality control principles to herbal
drugs. International Journal of Phytomedicine. 2009;1(1):4–8.
46. Prado JM, Veggi PC, Meireles MAA. Scale- up issues and cost of manufacturing bioactive compounds
by supercritical uid extraction and ultrasound assisted extraction. Global Food Security and Wellness. 2017:2017;377–433.
47. Choudhary N, Sekhon BS. An overview of advances in the standardization of herbal drugs. Journal of
Pharmaceutical Education and Research. 2011;2(2):55.
48. Enioutina EY, Salis ER, Job KM, Gubarev MI, Krepkova LV, Sherwin CM. Herbal Medicines: challenges
in the modern world. Part 5. status and current directions of complementary and alternative herbal medi­cine worldwide. Expert Review of Clinical Pharmacology. 2017;10(3):327–38.
49. Thomford NE, Dzobo K, Chimusa E, Andrae- Marobela K, Chirikure S, Wonkam A, et al. Personalized
herbal medicine? A roadmap for convergence of herbal and precision medicine biomarker innovations. OMICS: A Journal of Integrative Biology. 2018;22(6):375–91.
Regulatory Considerations for Herbal Products 457
50. Stargrove MB, Treasure J, McKee DL. Herb, nutrient, and drug interactions: clinical implications and
therapeutic strategies: Elsevier Health Sciences; 2007.
51. Rehman SU, Shahzad M, Ding X, Razzaq A. Impact of corporate motives for sustainable sourc-
ing: Key moderating role of regulatory pressure. Environmental Science and Pollution Research. 2023;30(27):71382–95.
52. Initiative CS, Golden JS, Vermeer D, Clemen B, Davie Nguyen M. An overview of ecolabels and sus-
tainability certications in the global marketplace. Nicholas Institute for Environmental Policy Solutions Duke University Interim Report Document. 2010:10–1.
53. Uhlenbrock L, Sixt M, Tegtmeier M, Schulz H, Hagels H, Ditz R, et al. Natural Products Extraction of
the Future—Sustainable Manufacturing Solutions for Societal Needs. Processes. 2018;6(10):177.
22

Present Challenges and Future Perspective of the Herbal Drug Industry

Mehtab Yasmeen
Department of Botany, Telangana Mahila Viswavidyalayam, Hyderabad, India
Mukul Machhindra Barwant
Department of Botany, Sanjivani Rural Education Society’s (SRES), Sanjivani Arts, Commerce and Science College, Kopargaon, India
Balwant Singh
Department of Botany, Dr. Ram Manohar Lohia Avadh University, Ayodhya, Uttar Pradesh, India
Odangowei Inetiminebi Ogidi
Department of Biochemistry, Faculty of Basic Medical Sciences, Bayelsa Medical University, Yenagoa, Nigeria

22.1 INTRODUCTION

Over the past few years, there has been an amazing growth in the herbal drug industry worldwide. This is mainly due to the increase in demands for plant products and a growing awareness about holistic therapy. Herbal drugs involve plants, or parts of plants, that provide an alternative method to modern medicines, treating the ailments but with less side effects. This new interest is mainly due to the practicing of traditional knowledge in many countries, increased awareness about dangerous outcomes of allopathy along with enormous body of scientic research data supporting the efciency of many herbal drugs. Although the industry of herbal drugs has been growing positively, it has not fully realized its potential because it faces a number of hurdles. Among these challenges are regulatory barriers, quality control concerns, and standardizing herbal products. Various regions have different ways in which they regulate herbal medicines, which complicates approval processes and access to markets. Furthermore, the problem of maintaining uniformity in the quality and safety of herbal products is consistent given the fact that both plant sources and harvesting methods differ, and so do processing techniques. The sector’s landscape is further complicated by unstandardized dos­ages and formulations which affect both consumer condence and clinical efciency. Moreover, the herbal drug market is plagued by issues of sustainability and ethical sourcing. The overharvesting of medicinal plants and the exploitation of biodiversity pose serious threats to the environment and local communities. Ethical sourcing practices and sustainable cultivation methods are imperative to safe­guarding the future of the industry and the ecosystems it relies upon. The growth of the herbal drug industry therefore also depends on science and technology. The combination of modern biotechno­logical treatments with classical ones leads to the improvement in the standards and effectiveness of the herbal drugs. Many such effective methods of extraction and formulation of these products could
458
Present Challenges and Future Perspective of the Herbal Drug Industry 459
have been used to arrive at a more standard and acceptable form of ‘herbal therapeutics’. Except for that, application of AI and digital technology in this area help to improve supply chain and traceability system for the herbal medicine and individualized prescription (Izah etal., 2023).
This chapter considers the current challenges facing the herbal drug industry and possible direc­tions for its further growth. The use of science- based innovations addressing these concerns will ensure that the industry enjoys long- term sustainable development and makes a signicant contribu­tion to global health.

22.2 EMERGING TRENDS AND INNOVATIONS

22.2.1 Biotechnology and genetic engineering

As it has been ascertained that plants can produce some chemicals which are benecial in the course of treatment, modern pharma research is gradually shifting towards these compounds. In this area, a lot of progress has been realized, and this has been as a result of the synthesis of these chemicals by employing biotechnology and synthetic biology methods (Ausländer etal., 2017). Since it turns out to be simple to produce enormous volumes of the pure constituent chemicals, this technique enhances the viability and safety of use of these medicine.
In fact, it is not wrong to say that a greater part of the modern medicines and therapies are derived from plant products and phytochemicals. Zajtchuk (1999) disclosed that biotechnology and syn­thetic biology have offered the new prospects for the drug development and approval. It will also enable the synthesis of new compounds in pharmaceutical industries that have even higher therapeu­tic values than the existing compounds in the market. This method has the propensity of altering the pharma industry through establishing productive and unique products which effectively address different diseases and diseases states (Gottweis, 1998). However, to that in cuts out the need to manually pick entire plants, an action that often leads to a destruction of the plant and space it occu­pies hence solving ecological problems. Bioreactors are containers that are cultivated under condi­tions that permit the growth of plant cells or microorganisms; these increase the synthesis rate of different compounds (Zhong, 2010). Probably, the genetic organization of these organisms may be redesigned to employ suboptimal metabolic engineering and the pathway engineering methods that will improve the efciency of production of the encouraged compounds (Deparis etal., 2017). In addition to improving the sustainability of production, such innovations have a positive impact on the quality and trustworthiness of the plant- derived compounds which are synthesized. At the same time, bioinformatics as well as computer aided modeling and high- throughput screening are all mainly game changer in the discovery of new products. An advanced procedure called ‘high­throughput screening’ involves the screening of thousands to millions of isolated chemicals or extracts of plants for activity against specic biological targets using robotics and computers (Ismail etal., 2018). This makes it possible to nd active chemicals rapidly. By contrast, virtual screening and molecular modeling methods are helpful in predicting the interaction among different chemical substances obtained from plants.
Virtual screening is a computer technique that assists in selecting possible medication that can be retrieved from large databases of chemical compounds. This process includes assessing the interac­tions between small molecule and proteins, together with other techniques in docking simulations and in molecular modeling (Reddy etal., 2007). It has been applied in optimizing currents drugs, identifying new lead molecules for drug development as a part of pharmaceutical realm (Singh and Bharadvaja, 2021). This enables one to grasp the hierarchical arrangements and the possible treat­ment regimes. As reported by Ambrosino etal. (2019), bioinformatics provides a plethora of infor­mation focuses on genes, metabolism, and pharmaceutics of these species. Such information is applied in the identication of new compounds and in the understanding of the biosynthesis pro­cesses. The technology integration also assists in identifying as well as enhancing plant- based com­pounds towards the enhancement of plant yielding, and quite successfully opens a new chapter of
460 Herbal Pharmacopeia
medication production. The molecular modeling method can be used to estimate the behavior and interaction of molecules and other molecular- based substances with the help of computers (Dhoundiyal and Alam, 2023). It is used to discover new drug molecules and therapeutic compounds against different diseases and also helps in studying the structure and functions of proteins, DNA, and other biological substances. These modern techniques provide a synergy of rather effective components to address environmental issues, as well as enhancing the methodical search and devel­opment of novelties on medications. Biotechnology and synthetic biology, which reduce environ­mental impact, are at the heart of the correct synthesis of compound parings originating from plants (Singh and Bharadvaja, 2021; Ogidi and Emaikwu, 2023a,b). As Sharma & Sarkar (2013) have stated, high- throughput screening and other computational methods are time- saving and systematic, on the one hand, and methodical, on the other hand, in recognizing the potential medicinal mole­cules. The knowledge of these molecules is enhanced by bioinformatics, thereby leading to the development of new medications (Wishart, 2005). In general, the application of biotechnology, which is inuenced by powerful computing equipment, contributes to the enhancement of the herbal pharmaceutical sector with improved environmental outcomes and also the faster production of new medications.

22.2.2 nanotechnology

The intrinsic components of the nanoparticles (NPs), which are surface- bound to the polymeric matrix, may include the active agents, which will have sizes ranging from 1 to 1000 nm. These can be used as drug carriers to increase the therapeutic window and bioavailability, provide regu­lated release, and shield different desired chemicals from the environment (Zielinska etal., 2020). Depending on the process used to make nanocapsules or nanospheres, one could coat nanopar­ticles. The medicine in nanocapsules is contained within a cell surrounded by a polymer mem­brane, whereas the drug in nanospheres is encased in a matrix that has particles physically scattered throughout it (Soppimath etal., 2001). Because of their exceptional stability and their capacity to transport both hydrophilic and hydrophobic molecules, nanoparticles are a promising option for the delivery of pharmaceuticals. It is also possible to administer them either orally or by means of inhalation. According to Gelperina (2005), these carriers might be made to enable the medication’s gradual, controlled release. Furthermore, Mughees et al.’s 2021 research emphasizes the useful­ness of nanoparticles in conjunction with phytochemicals and herbal extracts as a targeted antican­cer therapeutic approach, albeit one with some drawbacks. Nanoparticles can be used as effective medicine carriers because they are highly stable, have a high carrier capacity, and can contain both hydrophobic and hydrophilic compounds. In addition, they can be given orally using a number of methods, including inhalation. According to Gelperina (2005), these carriers might also be made to make it easier for the drugs to release matrix- regulated over a longer time frame. Mughees etal. (2021) state that polymeric nanoparticles work against cancer by delivering medications in a safe and effective manner when paired with phytochemicals and herbal extracts. Similarly, liposomes containing lipid nanoparticles are among the few lipidic nanoparticles. Liposomes are tiny lipid­containing vesicles with a diameter of 0.1–10 nm that have a watery core surrounded by two layers of phospholipid. Agrahari etal. (2016) state that there are three different types of liposomes based on size and lipid bilayers: tiny unilamellar vesicles, big uniagellar vesicles, and multilamellar vesicles. According to Eloy etal. (2017), it can be utilized to combine hydrophilic and lipophilic compounds. It is anticipated that using liposomes to target certain pharmaceuticals may improve the medications’ therapeutic effects, reduce any potential toxicity, and eliminate localized irritation.
Liposomes help deliver drugs to particular places with controlled release, change biodistribution, and boost solubility and bioavailability. Another advantage of using liposomes for parenteral distri­bution is the avoidance of rst- pass metabolism, limited gastrointestinal permeability, and deleteri­ous effects on the gastrointestinal tract (Shah etal., 2020). In 2020, Shariare etal. (2020) developed a liposomal drug delivery technique using Aphanamixis polystachya leaf extract to treat
Present Challenges and Future Perspective of the Herbal Drug Industry 461
neurological conditions such as Parkinson’s disease and Alzheimer’s disease. Solid lipid nanoparti­cles (SLNs) are the ideal alternative to colloidal approaches for targeted and controlled delivery. They contain hydrophilic and lipophilic medications and are made of biodegradable and biocompat­ible materials that range in size from 50 to 1000 nm (Manjunath etal., 2005). Since most lipids are biodegradable, SLNs offer remarkable biocompatibility. Both lipophilic and hydrophilic medica­tions can be included in SLNs, which provide controlled and regulated drug release. Furthermore, SLNs are less expensive than carriers made of surfactants or polymers (Mukherjee etal., 2009).
Hibiscus rosasinensis extract- loaded solid lipid nanoparticles, or HSLNs, were initially made with glycerol monostearate or beeswax as the substrate by Vijayanand etal. (2018). The form, sur­face charge, and size of the HSLNs were assessed. Tests were conducted on male Swiss albino mice to assess the antidepressant efcacy of the enhanced HSLNs. It was found that HSLNs with a nearly spherical morphology and a negative charge may be manufactured at as small as 175 nm by using the optimized approach. The in vivo experiment data showed that the test animals’ periods of immo­bility differed greatly. It was also found that HSLNs, at doses several times lower than those of the crude extract derived from native plants, could provide the same pharmacological effects. According to preliminary studies, solid lipid nanoparticle encapsulation of phytopharmaceuticals may enhance their in vivo efcacy (Vijayanand etal., 2018).

22.3 REGULATORY CHALLENGES AND OPPORTUNITIES

Each country has different legal standards for herbal medicines. In developing nations, the tradi­tion of using plants for treating diseases is quite popular among the public. However, the drug laws in many of these countries do not regulate these widely used herbal remedies (Chavan etal.,
2006). In most of the countries, herbal drug therapy relies on traditional knowledge of medicinal plants, provided do not harm for any regular ailments. However, in areas lacking traditional medi­cal knowledge, many serious illnesses are being treated with alternative therapies. Despite this, the belief that herbal medications are free from allergies or negative effects is incorrect, as they contain various potentially harmful substances. Most herbal medicine purchases occur over the counter in a traditional setting. Therefore, legal regulations are essential to conrm the effectiveness, quality, and safety of herbal remedies. Conducting clinical trials and assessing the potential harm of herbal treatments are necessary steps for maintaining the regulatory status of herbal pharmaceuticals. Laws regarding herbal medications vary from country to country (Mukherjee etal., 2006).

22.4 INTELLECTUAL PROPERTY RIGHTS

Basically, whenever innovations are considered the ndings of Western science are given impor­tance. However, many inventions that are protected by intellectual property rights (IPR) are known which are known due to years of traditional knowledge build up, taking into consideration of experi­ences of other countries. Curing a sickness that modern medicine does not know how to treat is one of the most researched elds, and new issues about the IPR of the local population continue to arise. Diverse viewpoints on the matter are presented by the different domains and relation of intellectual rights and property (Duteld, 2000).
The act of simply exploiting such plant- based knowledge without granting credit to the original author is known as “biopiracy,” and it is a current reality that has various legal repercussions and poses a threat to inventors in the future (Gollin, 1999). IPR has progressed into a standard protocol for original ownership of all traditional information and has helped to pave the way for different pos­sibilities for legal frameworks that guarantee benets return to the original nations and cultures. The value of biodiversity for human health is emphasized by the IPR debates. Throughout history, plants are known to be basic suppliers for pharmacy. However, over time, the rate at which civilizations and species are going extinct, and non- curable diseases have worsened health conditions. Therefore, there has been global discussion about the IPR associated with the use of plants as medicines, and
462 Herbal Pharmacopeia
their importance has become increasingly acknowledged (Moran, 1998). The Agreement on Trade Related Intellectual Property Systems (TRIPS), which creates common standards for intellectual property protection, has been the subject of intense discussion since its beginnings. This is because there are concerns that the implementation of TRIPS may result in pharmaceutical price increases, which would decrease people’s access to necessary medicines, particularly in developing nations. Much of the conversation thus far has surrounded the issue of contemporary medications. When considering the topic of IPR for such products, developing countries can see that the goals are well­dened and that established solutions exist to accomplish those goals; however, putting those strate­gies into practice may be challenging. With relation to conventional medicine, the same cannot be true. The preservation of traditional knowledge is not mentioned in TRIPS, and it does not recognize or differentiate between industry- based information and knowledge originating from indigenous communities. Access to biological and genetic resources, as well as local and indigenous groups’ understanding of their medicinal qualities, are all entwined with traditional medicine. Therefore, a thorough evaluation of the goals and the potential ramications of IPR protection for traditional medicine should be conducted at the national level (Timmerman, 2003).

22.4.1 conventional Medicine and rights to intellectual ProPerty

The traditional and Indigenous peoples of the world have made enormous contributions to the preservation of biodiversity and associated traditional medical knowledge. Regular ethnobotani­cal surveys and related research yield fresh insights into the treatment of a wide range of illnesses, therapies for skin and body enhancement, natural oils, and other health- related items. In an attempt to nd additional “explorations” about modern diseases from traditional and indigenous groups, the globalized economy is facing hurdles that are giving rise to new and complicated issues. The prop­erty rights of traditional or indigenous communities, who are considered the “inventors,” collide with the notion that sharing and access to the world’s biodiversity resources is a fundamental human right. Trade is the utilization of all resources—including ideas, resources, and conventional medi­cal procedures—for the goal of commercialization; it usually takes place with little benet to the country or community of origin. Vinblastine and vincristine, which are made from the Madagascar rosy periwinkle (Vinca sp.), are a well- known example. The company makes about $100 million a year from these drugs, but neither the government of Madagascar nor the shamans who gave the researchers the information have received any payment for their services.
Commercializing what are collective resources—often of a secret or sacred nature—violates human rights and is demeaning to the local way of life. Thanks to the following, IPRs: -recognize individual rights rather than collective rights; -require a specic act of “invention”; -simplify owner­ship regimes; -stimulate commercialization; -recognize only market values; -are expensive, compli­cated, and time- consuming; -are subject to economic powers and manipulation (Posey, 2002). The Convention on Biological Diversity (CBD) and IPR Moreover, several medicinal plants are in dan­ger of being extinct. The overuse of these plants to satisfy industrial and/or export demands may put people at risk (Newman, 1994). It is also a historical issue since it took place in the ancient Mediterranean region. For example, the plant recognized for its ability to prevent conception, Silphium, brought incredible wealth to the ancient residents of Cyrene, a coastal city in ancient Libya. But the overharvesting of the plant resulted in its demise and the loss of future economic benets (Sumner, 2001).
Controlling the trade in medicinal plants is therefore essential, ideally as part of a larger regula­tory framework addressing the sustainable use and protection of biological resources. Conservation is not only an essential ally in this struggle, but is also vital to the survival of traditional medicine in countries with high biodiversity. The Convention on Biological Diversity (CBD) is the only major international agreement that acknowledges indigenous communities as the owners of biodiversity and protects their right to keep it that way, although it is competing with the far more powerful advantages of TRIPS (Bodeker, 2000).
Present Challenges and Future Perspective of the Herbal Drug Industry 463
Indian literature dates back over two millennia, and makes early mention of the neem tree (Azadiracthta indica). It can be made into numerous goods, including fungicide, cosmetics, insect repellent, and pharmaceuticals for both humans and animals. Indian farmers used to soak neem seeds in water and then spray the resulting emulsion on their plants.
Neem was later popularized by Western merchants because it had fewer negative side effects than most chemical insecticides. At present, many patents covering neem products are pending in Europe, the US, and India. In 1993, for example, P.J. Margo Private Ltd. began to produce and distribute neem biopesticides in India. Two years later, in 1995, following public demonstrations against the initiative, a number of advocacy organizations united to contest the US and European patents on the grounds that the product or procedure was not an innovative one and that Indians had been utilizing such products in the same way for generations. However, the US patent is still enforceable, although the European Patent Ofce has revoked the patent in Europe (Finger, 2003).

22.5 GLOBAL MARKET TRENDS

Pharmaceutical rms have beneted greatly from products generated from traditional knowledge (TK), with indigenous plant knowledge playing a critical role in this. These businesses are espe­cially drawn to TK because of to the costliness of screening new medications. Usually, only one in every 10,000 molecules is developed into a new medication; this process can take up to 15 years and may cost over $800 million. There are about 121 prescription plant- based medications in the world, with around half of them coming from tropical areas. Partly because of their climate, tropi­cal countries are valuable because of their enormous biological and chemical variety. While tropi­cal plants have evolved chemical defenses to withstand minimal seasonal respite from predators, temperate climates experience a reduction in plant predators throughout winter. Additionally, these plant- based compounds may have therapeutic advantages for human health (Moran, 1998). In the past, businesses from more developed northern nations have produced pharmaceutical goods using the traditional knowledge of therapeutic herbs from less developed, biologically diverse tropical nations without making any payment to the knowledge providers. There is an increasing trend in the use of herbal medicines globally, and the global market for plant- based medications is estimated to be worth $169.6 billion (Kanhere, 2024).
Traditional medicine has two distinct meanings in both modern Western countries and develop­ing nations. Because it is accessible and affordable, traditional medicine plays a vital role in health systems in underdeveloped nations.
Peria (2001) claims that traditional medicine addresses concerns about technological transfer, cultural heritage preservation, and biodiversity conservation. On the other hand, traditional medi­cine is also increasingly seen as a choice or an alternative in contemporary nations. Popular and useful herbal species are in greater demand (8–15% yearly) in Europe, North America, and Asia (Grünwald and Büttel, 1996). Cultural variations impact the application of traditional medicine; according to a poll conducted in the United States, just 3% of respondents said they had used tradi­tional medicine in the preceding year (Eisenberg etal., 1993). By contrast, 31% of respondents in Germany, a country with a high prevalence of traditional herbal therapy, stated they have used over­the- counter phytopharmaceutical preparations in a similar period (BAH, 2002).

22.6 CHALLENGES AND LIMITATIONS

The overextraction of plant species for medicinal components can place some plant species in dan­ger and lead to the depletion of natural resources. Collection methods that are not sustainable can degrade habitats, upend ecosystems, and endanger biodiversity. In order to safeguard ecosystems and the indigenous populations that depend on them, these concerns emphasize the need for sus­tainable and ethical sourcing practices as well as the preservation of medicinal plant species. Plant genetics, environmental circumstances, and harvesting practices are among the variables that can